BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$54.14
-1.41 (-2.54%)
▼
5d:
+0.02%
30d:
-11.41%
90d:
-9.77%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
BMRN is down 8.2% this week, but smart money is accumulating calls. Top strike: $65 2026-04-17 with 858 OI. Call ratio: 67% View Scanner →
Strength: 5.7/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$135.07
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$83.87
35.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $54.14, which is considered oversold relative to its 30-day fair value range of $55.95 to $62.08. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.0) compared to its historical average (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This pessimistic expectation contrasts with the company's recent 124.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BMRN is in a uptrend. The price is currently testing key support at $53.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $88.87 (+64.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BMRN is in a uptrend. The price is currently testing key support at $53.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $88.87 (+64.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$55.95 -
$62.08
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding BMRN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.1% below Wall St target ($88.87)
Fair Price Analysis
30-Day Fair Range
$55.95 -
$62.08
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$53.36
Resistance Level
$58.81
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.04
Wall Street Target
$88.87
(+64.1%)
Revenue Growth (YoY)
17.0%
Earnings Growth (YoY)
124.3%
Profit Margin
10.8%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
8.0 vs 10.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$49.75
(-8%)
2-Year Target
$45.72
(-16%)
3-Year Target
$42.02
(-22%)
3-Yr Target (if PE normalizes)
(PE: 8→10)
$53.83
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 26.1%)
$302.49
(+459%)
Base:
(SPY PE: 8.0, Growth: 26.1%)
$108.57
(+101%)
Bear:
(PE: 6.8, Growth: 26.1%)
$92.29
(+71%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 30.07 | Current EPS (TTM): $1.80
Bull Case
$119.09
(+117%)
Analyst growth 100.0%, PE expands to 33.1
Base Case
$108.26
(+98%)
Market implied 100.0%, PE stable at 30.1
Bear Case
$36.81
(-33%)
Severe decline -20.0%, PE contracts to 25.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.0 to 10.3
Stabilization Target:
$69.36
(+28.1%)
PE Expansion Potential:
+28.1%
Share & Embed Analysis
Last updated: March 30, 2026 7:04 AM ET
Data refreshes hourly during market hours. Next update: 8:04 AM
Data refreshes hourly during market hours. Next update: 8:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 55 HOLD |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 62 BUY |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
